XBiotech Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation British Columbia, Canada
Business Address 5217 WINNEBAGO LANE, AUSTIN, TX, 78744
Mailing Address 5217 WINNEBAGO LANE, AUSTIN, TX, 78744
Phone 512-386-2900
Fiscal Year End 1231
EIN 000000000
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | January 23, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 23, 2026 | View on SEC |
| 8-K Current report of material events | December 9, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 12, 2025 | View on SEC |
| 8-K/A Current report amendment | October 15, 2025 | View on SEC |
| 8-K Current report of material events | October 3, 2025 | View on SEC |
Material Events
8-K Leadership Change December 9, 2025
High Impact
- John Simard is stepping down as President and CEO of XBiotech Inc. after 21 years of service.
- Mr. Simard will remain as Chairman of the Board of Directors and will continue to advise the company as a consultant.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.